Irinotecan Hydrochloride Injection 40 & 100 mg

Irinotecan Hydrochloride Inj 40 & 100 mg  is an anti-neoplastic agent belonging to the class of topoisomerase I inhibitors. It is a semi-synthetic derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I. Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I – DNA complex and prevent religation of these singlestrand breaks in the DNA. Current research suggests that cytotoxicity of irinotecan hydrochloride is due to double strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by Topoisomerase I, DNA, and either irinotecan hydrochloride or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

3s corporation is Supplier,Exporter ,Wholesaler  for Irinotecan Hydrochloride Inj 40 & 100 mg in India.

We even  offer contract manufacturing services from WHO GMP approved factories.

 

A reduction in the starting dose by one dose level of Irinotecan Hydrochloride Injection, USP may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.

Common side effects (≥30%) observed in single agent therapy clinical studies are:

nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia.

Serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.